Evotec SE ADR - Asset Resilience Ratio
Evotec SE ADR (EVO) has an Asset Resilience Ratio of 3.47% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Evotec SE ADR (EVO) strategic asset index to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2003–2025)
This chart shows how Evotec SE ADR's Asset Resilience Ratio has changed over time. See EVO net asset quality score to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Evotec SE ADR's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Evotec SE ADR.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $56.91 Million | 3.47% |
| Total Liquid Assets | $56.91 Million | 3.47% |
Asset Resilience Insights
- Limited Liquidity: Evotec SE ADR maintains only 3.47% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Evotec SE ADR Industry Peers by Asset Resilience Ratio
Compare Evotec SE ADR's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Aurobindo Pharma Limited
NSE:AUROPHARMA |
Drug Manufacturers - Specialty & Generic | 1.28% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026 |
Drug Manufacturers - Specialty & Generic | -0.89% |
|
Zhejiang Hisoar Pharmaceutical Co Ltd
SHE:002099 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Xeris Pharmaceuticals Inc
NASDAQ:XERS |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Procter & Gamble Health Limited
NSE:PGHL |
Drug Manufacturers - Specialty & Generic | 33.01% |
Annual Asset Resilience Ratio for Evotec SE ADR (2003–2025)
The table below shows the annual Asset Resilience Ratio data for Evotec SE ADR.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 3.25% | $57.85 Million | $1.78 Billion | -1.47pp |
| 2024-12-31 | 4.73% | $90.41 Million | $1.91 Billion | +0.67pp |
| 2023-12-31 | 4.05% | $93.20 Million | $2.30 Billion | -9.53pp |
| 2022-12-31 | 13.58% | $306.61 Million | $2.26 Billion | +6.46pp |
| 2021-12-31 | 7.12% | $159.17 Million | $2.24 Billion | +3.17pp |
| 2020-12-31 | 3.95% | $72.62 Million | $1.84 Billion | +0.45pp |
| 2019-12-31 | 3.50% | $48.25 Million | $1.38 Billion | -1.79pp |
| 2018-12-31 | 5.29% | $40.82 Million | $771.88 Million | +0.11pp |
| 2017-12-31 | 5.18% | $34.56 Million | $667.27 Million | -7.32pp |
| 2016-12-31 | 12.50% | $43.92 Million | $351.37 Million | -18.85pp |
| 2015-12-31 | 31.35% | $90.46 Million | $288.54 Million | +13.01pp |
| 2014-12-31 | 18.35% | $41.21 Million | $224.60 Million | -4.74pp |
| 2013-12-31 | 23.09% | $52.49 Million | $227.38 Million | +11.30pp |
| 2012-12-31 | 11.79% | $26.57 Million | $225.43 Million | -9.30pp |
| 2011-12-31 | 21.08% | $46.01 Million | $218.21 Million | -3.65pp |
| 2010-12-31 | 24.73% | $47.45 Million | $191.86 Million | +7.38pp |
| 2009-12-31 | 17.35% | $25.43 Million | $146.60 Million | +1.47pp |
| 2008-12-31 | 15.87% | $29.03 Million | $182.90 Million | -12.09pp |
| 2007-12-31 | 27.97% | $58.14 Million | $207.88 Million | +17.98pp |
| 2006-12-31 | 9.99% | $20.53 Million | $205.53 Million | -40.25pp |
| 2005-12-31 | 50.24% | $93.50 Million | $186.11 Million | -34.42pp |
| 2004-12-31 | 84.66% | $60.03 Million | $70.91 Million | +9.14pp |
| 2003-12-31 | 75.52% | $31.51 Million | $41.73 Million | -- |
About Evotec SE ADR
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just " Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammati… Read more